

Gianfranco Balboni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9306273/publications.pdf>

Version: 2024-02-01

123
papers

3,430
citations

136940

32
h-index

206102

48
g-index

124
all docs

124
docs citations

124
times ranked

3103
citing authors

#	ARTICLE	IF	CITATIONS
1	Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment. <i>Metabolites</i> , 2020, 10, 412.	2.9	116
2	Evaluation of the Dmt-Tic Pharmacophore: Conversion of a Potent δ -Opioid Receptor Antagonist into a Potent δ Agonist and Ligands with Mixed Properties. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 713-720.	6.4	93
3	Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats. <i>Brain Research</i> , 2006, 1069, 172-181.	2.2	87
4	Evolution of the Dmt-Tic Pharmacophore: N-Terminal Methylated Derivatives with Extraordinary δ Opioid Antagonist Activity. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3100-3108.	6.4	85
5	Potent δ -Opioid Receptor Agonists Containing the Dmt-Tic Pharmacophore. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5556-5563.	6.4	85
6	The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 14646-14651.	7.1	85
7	Indole derivatives as multifunctional drugs: Synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity of indole hydrazones. <i>Bioorganic Chemistry</i> , 2019, 85, 568-576.	4.1	83
8	δ , but not μ , opioid receptor stabilizes K ⁺ homeostasis by reducing Ca ²⁺ influx in the cortex during acute hypoxia. <i>Journal of Cellular Physiology</i> , 2007, 212, 60-67.	4.1	80
9	Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH ₂ -COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist. <i>Peptides</i> , 2008, 29, 93-103.	2.4	75
10	Synthesis and evaluation of anticancer activity of 2-arylamino-6-trifluoromethyl-3-(hydrazonocarbonyl)pyridines. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6158-6165.	3.0	75
11	Further Studies on the Dmt-Tic Pharmacophore: Hydrophobic Substituents at the C-Terminus Endow δ Antagonists To Manifest δ Agonism or δ Antagonism. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5010-5019.	6.4	71
12	Synthesis and in vitro antitumor activity of new 4,5-dihydropyrazole derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6238-6248.	3.0	69
13	Synthesis and Pharmacological Activity of Deltorphan and Dermorphan-Related Glycopeptides. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2948-2952.	6.4	58
14	Triazine Compounds as Antagonists at Bv8-Prokineticin Receptors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7635-7639.	6.4	55
15	Activation of DOR Attenuates Anoxic K ⁺ Derangement via Inhibition of Na ⁺ Entry in Mouse Cortex. <i>Cerebral Cortex</i> , 2008, 18, 2217-2227.	2.9	53
16	Interaction and reactivity of synthetic aminoisoflavones with metal-free and metal-associated amyloid- β . <i>Chemical Science</i> , 2014, 5, 4851-4862.	7.4	50
17	6-N,N-Dimethylamino-2,3-naphthalimide: A New Environment-Sensitive Fluorescent Probe in δ - and δ -Selective Opioid Peptides. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3653-3658.	6.4	48
18	Phe3-substituted analogs of deltorphan C. Spatial conformation and topography of the aromatic ring in peptide recognition by δ opioid receptors. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 3748-3756.	6.4	46

#	ARTICLE	IF	CITATIONS
19	Conformational Dynamics of Kir3.1/Kir3.2 Channel Activation Via κ -Opioid Receptors. <i>Molecular Pharmacology</i> , 2013, 83, 416-428.	2.3	45
20	Synthesis and biological evaluation of novel acylhydrazone derivatives as potential antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6592-6599.	3.0	42
21	Opioid Diketopiperazines: Synthesis and Activity of a Prototypic Class of Opioid Antagonists. <i>Biological Chemistry</i> , 1997, 378, 19-29.	2.5	41
22	δ -Opioid receptors protect from anoxic disruption of Na ⁺ homeostasis via Na ⁺ channel regulation. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 3505-3516.	5.4	41
23	Design of δ -opioid peptide antagonists for emerging drug applications. <i>Drug Discovery Today</i> , 1998, 3, 284-294.	6.4	40
24	Bv8/prokineticin 2 is involved in Al^{2+} -induced neurotoxicity. <i>Scientific Reports</i> , 2015, 5, 15301.	3.3	40
25	Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro. <i>Neuropharmacology</i> , 2016, 108, 39-48.	4.1	40
26	Benzofuran hydrazones as potential scaffold in the development of multifunctional drugs: Synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 118-125.	5.5	40
27	Stereospecificity of amino acid side chains in deltorphin defines binding to opioid receptors. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 1222-1227.	6.4	39
28	Evolution of the Bifunctional Lead $\frac{1}{4}$ Agonist/ δ Antagonist Containing the 2,6-Dimethyl-L-tyrosine ^{1,2,3,4} -Tetrahydroisoquinoline-3-carboxylic Acid (Dmt ¹ Tic) Opioid Pharmacophore. <i>ACS Chemical Neuroscience</i> , 2010, 1, 155-164.	3.5	39
29	Synthesis and structure-activity relationships of deltorphins analogs. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 1656-1661.	6.4	38
30	δ -Opioid receptors upregulate excitatory amino acid transporters in mouse astrocytes. <i>British Journal of Pharmacology</i> , 2014, 171, 5417-5430.	5.4	35
31	Effect of δ -Opioid Receptor Activation on BDNF-TrkB vs. TNF- α in the Mouse Cortex Exposed to Prolonged Hypoxia. <i>International Journal of Molecular Sciences</i> , 2013, 14, 15959-15976.	4.1	34
32	A novel mechanism for cytoprotection against hypoxic injury: δ -opioid receptor-mediated increase in Nrf2 translocation. <i>British Journal of Pharmacology</i> , 2015, 172, 1869-1881.	5.4	34
33	Prokineticin 2 Upregulation in the Peripheral Nervous System Has a Major Role in Triggering and Maintaining Neuropathic Pain in the Chronic Constriction Injury Model. <i>BioMed Research International</i> , 2015, 2015, 1-15.	1.9	32
34	Design, Synthesis and Evaluation of Antiproliferative Activity of New Benzimidazolehydrazones. <i>Molecules</i> , 2016, 21, 579.	3.8	32
35	Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy. <i>Journal of Neuroinflammation</i> , 2019, 16, 89.	7.2	32
36	Synthesis and activity of 3-pyridylamine ligands at central nicotinic receptors. <i>European Journal of Medicinal Chemistry</i> , 2000, 35, 979-988.	5.5	31

#	ARTICLE	IF	CITATIONS
37	Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression <i>in Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2017, 23, 7130-7140.	7.0	31
38	Synthesis and activity profiles of new dermorphin-(1-4) peptide analogs. <i>Journal of Medicinal Chemistry</i> , 1987, 30, 1538-1542.	6.4	30
39	Inhibitory properties of ibuprofen and its amide analogues towards the hydrolysis and cyclooxygenation of the endocannabinoid anandamide. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2013, 28, 172-182.	5.2	30
40	Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen. <i>European Journal of Pharmacology</i> , 2013, 720, 383-390.	3.5	30
41	Opioid Diketopiperazines: Refinement of the μ Opioid Antagonist Pharmacophore. <i>Biological Chemistry</i> , 1997, 378, 107-114.	2.5	29
42	New Opioid Designed Multiple Ligand from Dmt-Tic and Morphinan Pharmacophores. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5640-5643.	6.4	29
43	Critical role for prokineticin 2 in CNS autoimmunity. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e95.	6.0	29
44	Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue. <i>European Journal of Pharmacology</i> , 2000, 406, R1-R3.	3.5	28
45	Prokineticin 2 promotes and sustains neuroinflammation in vincristine treated mice: Focus on pain and emotional like behavior. <i>Brain, Behavior, and Immunity</i> , 2019, 82, 422-431.	4.1	28
46	Synthesis and evaluation of antioxidant and antiproliferative activity of 2-arylbenzimidazoles. <i>Bioorganic Chemistry</i> , 2020, 94, 103396.	4.1	28
47	Synthesis and pharmacological activity of partially modified retro-inverso dermorphin tetrapeptides. <i>Journal of Medicinal Chemistry</i> , 1985, 28, 769-774.	6.4	27
48	DOR activation inhibits anoxic/ischemic Na ⁺ influx through Na ⁺ channels via PKC mechanisms in the cortex. <i>Experimental Neurology</i> , 2012, 236, 228-239.	4.1	27
49	Discovery of thiazolin-4-one-based aromatic sulfamates as a new class of carbonic anhydrase isoforms I, II, IV, and IX inhibitors. <i>Bioorganic Chemistry</i> , 2018, 77, 293-299.	4.1	27
50	Treatment With the Delta Opioid Agonist UFP-512 Alleviates Chronic Inflammatory and Neuropathic Pain: Mechanisms Implicated. <i>Frontiers in Pharmacology</i> , 2019, 10, 283.	3.5	27
51	Antagonism of the Prokineticin System Prevents and Reverses Allodynia and Inflammation in a Mouse Model of Diabetes. <i>PLoS ONE</i> , 2016, 11, e0146259.	2.5	27
52	Highly Selective Fluorescent Analogue of the Potent μ -Opioid Receptor Antagonist Dmt-Tic. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6541-6546.	6.4	26
53	Effect of Lysine at C-Terminus of the Dmt-Tic Opioid Pharmacophore. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5610-5617.	6.4	25
54	Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3063-3066.	2.2	25

#	ARTICLE	IF	CITATIONS
55	A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2014, 81, 334-340.	5.5	25
56	Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3850-3853.	2.2	25
57	Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoforms II, IV and IX inhibitory efficacy. <i>Bioorganic Chemistry</i> , 2018, 77, 633-639.	4.1	25
58	Design and Solution Structure of a Partially Rigid Opioid Antagonist Lacking the Basic Center - Models of Antagonism. <i>FEBS Journal</i> , 1997, 247, 66-73.	0.2	24
59	Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei. <i>Peptides</i> , 2000, 21, 1663-1671.	2.4	24
60	A new opioid designed multiple ligand derived from the μ opioid agonist endomorphin-2 and the δ opioid antagonist pharmacophore Dmt-Tic. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 6876-6881.	3.0	24
61	Synthesis and Evaluation of Paracetamol Esters As Novel Fatty Acid Amide Hydrolase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2286-2298.	6.4	24
62	Structure-activity relationship with pyrazoline-based aromatic sulfamates as carbonic anhydrase isoforms I, II, IX and XII inhibitors: Synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111638.	5.5	24
63	Dmt-Tic-OH, a highly selective and potent δ -opioid dipeptide receptor antagonist after systemic administration in the mouse. <i>Life Sciences</i> , 1996, 59, PL93-PL98.	4.3	23
64	Assessment of substitution in the second pharmacophore of Dmt-Tic analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 2745-2748.	2.2	22
65	Further Studies on Lead Compounds Containing the Opioid Pharmacophore Dmt-Tic. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5109-5117.	6.4	22
66	Dehydro δ -dermorphins. <i>International Journal of Peptide and Protein Research</i> , 1986, 28, 262-273.	0.1	22
67	Conformationally constrained opioid ligands: The Dmt-Aba and Dmt-Aia versus Dmt-Tic scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 433-437.	2.2	22
68	Ligands Raise the Constraint That Limits Constitutive Activation in G Protein-coupled Opioid Receptors. <i>Journal of Biological Chemistry</i> , 2013, 288, 23964-23978.	3.4	22
69	Synthesis of 2-Amino-5-pyrimidinecarbonitrile Derivatives. <i>Synthesis</i> , 1991, 1991, 529-530.	2.3	21
70	Dehydro δ -dermorphins. <i>International Journal of Peptide and Protein Research</i> , 1986, 28, 254-261.	0.1	21
71	Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline α -carboxylic acid at position 2. <i>International Journal of Peptide and Protein Research</i> , 1995, 45, 567-573.	0.1	21
72	Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an <i>in vitro</i> model of Alzheimer's disease. <i>Neuropharmacology</i> , 2017, 116, 82-97.	4.1	21

#	ARTICLE	IF	CITATIONS
73	Synthesis and opioid activity of N,N-Dimethyl-Dmt-Tic-NH-CH(R)-R ² analogues: acquisition of potent $\hat{\nu}$ antagonist. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 5435-5441.	3.0	19
74	Direct Influence of C-Terminally Substituted Amino Acids in the Dmt ⁺ Tic Pharmacophore on $\hat{\nu}$ -Opioid Receptor Selectivity and Antagonism. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4066-4071.	6.4	19
75	Synthesis and opioid activity of partial retro ⁺ inverso analogs of dermorphin. <i>International Journal of Peptide and Protein Research</i> , 1985, 25, 526-533.	0.1	19
76	Dmt-Tic-NH-CH ₂ -Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies. <i>Peptides</i> , 2006, 27, 3322-3330.	2.4	18
77	Orally administered H-Dmt-Tic-Lys-NH-CH ₂ -Ph (MZ-2), a potent $\hat{\mu}$ - $\hat{\nu}$ -opioid receptor antagonist, regulates obese-related factors in mice. <i>European Journal of Pharmacology</i> , 2009, 616, 115-121.	3.5	18
78	The prokineticin receptor antagonist PC1 rescues memory impairment induced by $\hat{\nu}$ ² amyloid administration through the modulation of prokineticin system. <i>Neuropharmacology</i> , 2019, 158, 107739.	4.1	18
79	Response to Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors. <i>Biophysical Journal</i> , 2021, 120, 178-181.	0.5	16
80	Conversion of the Potent $\hat{\nu}$ -Opioid Agonist H-Dmt-Tic-NH-CH ₂ -Bid into $\hat{\nu}$ -Opioid Antagonists by N-Benzimidazole Alkylation ¹ . <i>Journal of Medicinal Chemistry</i> , 2005, 48, 8112-8114.	6.4	15
81	Hydrogen Sulfide Induced Disruption of Na ⁺ Homeostasis in the Cortex. <i>Toxicological Sciences</i> , 2012, 128, 198-208.	3.1	15
82	Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5619-5625.	3.0	15
83	Sulfonamide/sulfamate switch with a series of piperazinylureido derivatives: Synthesis, kinetic and in silico evaluation as carbonic anhydrase isoforms I, II, IV, and IX inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111896.	5.5	15
84	Appliance of the piperidinyl-hydrazidoureido linker to benzenesulfonamide compounds: Synthesis, in vitro and in silico evaluation of potent carbonic anhydrase II, IX and XII inhibitors. <i>Bioorganic Chemistry</i> , 2020, 98, 103728.	4.1	15
85	$\hat{\nu}$ -Opioid Receptor Activation Modified MicroRNA Expression in the Rat Kidney under Prolonged Hypoxia. <i>PLoS ONE</i> , 2013, 8, e61080.	2.5	15
86	Crystal Structures of Dipeptides Containing the Dmt-Tic Pharmacophore. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 5506-5513.	6.4	14
87	New 2 ⁺ ,6 ⁻ -Dimethyl-l-tyrosine (Dmt) Opioid Peptidomimetics Based on the Aba-Gly Scaffold. Development of Unique $\hat{\nu}$ / ₄ -Opioid Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3990-3993.	6.4	13
88	Role of 2 ⁺ ,6 ⁻ -dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6024-6030.	3.0	13
89	Attenuating Ischemic Disruption of K ⁺ Homeostasis in the Cortex of Hypoxic-Ischemic Neonatal Rats: DOR Activation vs. Acupuncture Treatment. <i>Molecular Neurobiology</i> , 2016, 53, 7213-7227.	4.0	13
90	$\hat{\nu}$ -Opioid Receptor Activation Attenuates Hypoxia/MPP ⁺ -Induced Downregulation of PINK1: a Novel Mechanism of Neuroprotection Against Parkinsonian Injury. <i>Molecular Neurobiology</i> , 2019, 56, 252-266.	4.0	13

#	ARTICLE	IF	CITATIONS
91	Prokineticin 1 "prokineticin receptor 1 signaling promotes angiogenesis in the porcine endometrium during pregnancy". <i>Biology of Reproduction</i> , 2020, 103, 654-668.	2.7	13
92	Influence of the Side Chain Next to C-Terminal Benzimidazole in Opioid Pseudopeptides Containing the Dmt-Tic Pharmacophore. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5556-5559.	6.4	12
93	Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 799-803.	5.5	12
94	Novel 2-amino-isoflavones exhibit aryl hydrocarbon receptor agonist or antagonist activity in a species/cell-specific context. <i>Toxicology</i> , 2012, 297, 26-33.	4.2	12
95	In-Vitro Evaluation of Antioxidant, Antiproliferative and Photo-Protective Activities of Benzimidazolehydrazone Derivatives. <i>Pharmaceuticals</i> , 2020, 13, 68.	3.8	12
96	Inhibition of human multidrug resistance P-glycoprotein 1 by analogues of a potent μ -opioid antagonist. <i>Brain Research</i> , 2001, 902, 131-134.	2.2	11
97	Role of benzimidazole (Bid) in the μ -opioid agonist pseudopeptide H-Dmt-Tic-NH-CH ₂ -Bid (UFP-502). <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3032-3038.	3.0	11
98	Synthesis and in vitro evaluation of piperazinyl-ureido sulfamates as steroid sulfatase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 182, 111614.	5.5	11
99	Hydrogen Sulfide Inhibits Inflammatory Pain and Enhances the Analgesic Properties of Delta Opioid Receptors. <i>Antioxidants</i> , 2021, 10, 1977.	5.1	11
100	Inhibition of the development of morphine tolerance by a potent dual μ / δ -opioid antagonist, H-Dmt-Tic-Lys-NH-CH ₂ -Ph. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 651-657.	2.9	10
101	Synthesis, pharmacological evaluation and conformational investigation of endomorphin-2 hybrid analogues. <i>Molecular Diversity</i> , 2013, 17, 19-31.	3.9	10
102	Design, synthesis, and anti-HIV-1 activity of 1-substituted 3-(3,5-dimethylbenzyl)triazine derivatives. <i>Antiviral Chemistry and Chemotherapy</i> , 2015, 24, 62-71.	0.6	10
103	Opposite Roles of μ - and δ -Opioid Receptors in BACE1 Regulation and Alzheimer's Injury. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 88.	3.7	10
104	Synthesis of a Potent and Selective ¹⁸ F-Labeled μ -Opioid Receptor Antagonist Derived from the Dmt-Tic Pharmacophore for Positron Emission Tomography Imaging. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1817-1823.	6.4	9
105	The Antagonism of the Prokineticin System Counteracts Bortezomib Induced Side Effects: Focus on Mood Alterations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10256.	4.1	9
106	μ -opioid receptor activation protects against Parkinson's disease-related mitochondrial dysfunction by enhancing PINK1/Parkin-dependent mitophagy. <i>Aging</i> , 2020, 12, 25035-25059.	3.1	9
107	Novel multiple opioid ligands based on 4-aminobenzazepinone (Aba), azepinoindole (Aia) and tetrahydroisoquinoline (Tic) scaffolds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1610-1613.	2.2	8
108	From the Potent and Selective δ Opioid Receptor Agonist H-Dmt-d-Arg-Phe-Lys-NH ₂ to the Potent μ Antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5608-5611.	6.4	7

#	ARTICLE	IF	CITATIONS
109	Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 3143-3151.	3.0	7
110	Differential inflammation-mediated function of prokineticin 2 in the synovial fibroblasts of patients with rheumatoid arthritis compared with osteoarthritis. <i>Scientific Reports</i> , 2021, 11, 18399.	3.3	7
111	Hydrogen Sulfide Increases the Analgesic Effects of $\hat{\mu}$ - and $\hat{\iota}$ -Opioid Receptors during Neuropathic Pain: Pathways Implicated. <i>Antioxidants</i> , 2022, 11, 1321.	5.1	7
112	Synthesis and biological activity of carboxyl terminally extended dermorphins. <i>International Journal of Peptide and Protein Research</i> , 1986, 28, 274-281.	0.1	6
113	Prokineticin Receptor 1 Antagonist PC-10 as a Biomarker for Imaging Inflammatory Pain. <i>Journal of Nuclear Medicine</i> , 2011, 52, 600-607.	5.0	6
114	Inhibitory effect of positively charged triazine antagonists of prokineticin receptors on the transient receptor vanilloid type-1 (TRPV1) channel. <i>Pharmacological Research</i> , 2015, 99, 362-369.	7.1	6
115	Evidence-Based View of Safety and Effectiveness of Prokineticin Receptors Antagonists during Pregnancy. <i>Biomedicines</i> , 2021, 9, 309.	3.2	6
116	Opioid peptides Synthesis and binding properties of dermorphin related heptapeptides. <i>International Journal of Peptide and Protein Research</i> , 1989, 33, 94-102.	0.1	3
117	Hair Growth Promotion by $\hat{\iota}$ -Opioid Receptor Activation. <i>Biomolecules and Therapeutics</i> , 2021, 29, 643-649.	2.4	3
118	A Critical Role of $\hat{\iota}$ -Opioid Receptor in Anti-microglial Activation Under Stress. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	3.4	3
119	Characterization of N,N(Me)2-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist. <i>NeuroReport</i> , 2000, 11, 2083-2086.	1.2	2
120	Ultrasensitive antagonists of the d-opioid receptor. <i>Expert Opinion on Therapeutic Targets</i> , 1998, 2, 45-47.	1.0	0
121	TRPV1 modulators: Synthesis and in vitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinyurea derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015, 100, 129-138.	5.5	0
122	Computational Chemistry and Opioidmimetics: Receptor-Ligand Interactions of Dmt-Tic Peptides. , 2001, , 851-852.		0
123	Generation of New Dmt-Tic $\hat{\iota}$ Opioid Antagonists: N-Alkylation. , 2002, , 603-604.		0